DEXA Bone Density: Which Tests to Order Alongside

What DEXA Bone Density Actually Measures

Dual-energy X-ray absorptiometry (DEXA) quantifies bone mineral density at the lumbar spine (L1 through L4), femoral neck, and total hip. The result is an areal density in g/cm², then converted to a T-score comparing you to a healthy 30-year-old reference population. The World Health Organization defines osteopenia as a T-score between -1.0 and -2.5, and osteoporosis as -2.5 or lower [2].

That number, however, is a snapshot. It does not reveal the metabolic process behind bone loss. A patient with a T-score of -2.7 from untreated celiac malabsorption needs a very different intervention than one with the same score from primary hyperparathyroidism. This is why the Endocrine Society's 2020 clinical practice guideline explicitly recommends a secondary-cause workup at the time of diagnosis [3]. Ordering DEXA alone is incomplete care.

The Z-score matters too. It compares BMD to age-matched and sex-matched peers. A Z-score below -2.0 in a premenopausal woman or a man under 50 strongly suggests an underlying medical condition and triggers a more extensive lab evaluation per ISCD official positions [4].

The Core Paired Panel: Vitamin D, PTH, and Calcium

Every patient who receives a DEXA scan showing osteopenia or osteoporosis should have serum 25-hydroxyvitamin D, intact parathyroid hormone (PTH), and serum calcium drawn. This trio answers a clinical question DEXA cannot: is the skeleton being actively robbed?

25-hydroxyvitamin D is the body's circulating storage form. The Endocrine Society defines deficiency as a level below 20 ng/mL and insufficiency as 20 to 29 ng/mL [5]. A 2011 NHANES analysis found that 41.6% of U.S. adults were vitamin D deficient [1]. Because vitamin D deficiency triggers secondary hyperparathyroidism (the parathyroid glands ramp up PTH to pull calcium from bone), even mild deficiency accelerates bone resorption.

Intact PTH distinguishes primary hyperparathyroidism (autonomous gland overactivity, often from an adenoma) from secondary hyperparathyroidism (a response to low vitamin D or renal calcium wasting). In primary hyperparathyroidism, PTH is elevated alongside normal-to-high calcium. In secondary disease, PTH rises but calcium stays low or normal. The distinction changes treatment entirely. Surgery for primary disease; vitamin D repletion for secondary.

Serum calcium, ideally albumin-corrected, closes the diagnostic triangle. Hypercalcemia with elevated PTH points toward a parathyroid adenoma. Hypocalcemia with elevated PTH suggests vitamin D deficiency or chronic kidney disease. The AACE/ACE 2020 clinical practice guidelines for postmenopausal osteoporosis list all three labs as first-line tests in their diagnostic algorithm [6].

Bone Turnover Markers: CTX and P1NP

Bone turnover markers (BTMs) tell you how fast bone is being broken down and rebuilt right now. DEXA, by contrast, reflects cumulative density over years. The two most clinically validated BTMs are CTX (a resorption marker) and P1NP (a formation marker).

Serum CTX (C-terminal telopeptide of type I collagen) is released when osteoclasts degrade bone matrix. A fasting morning blood draw is required because CTX shows significant diurnal variation and a postprandial drop of 20% to 30% [7]. Elevated CTX in a patient with low BMD confirms active high-turnover bone loss and predicts fracture risk independently of DEXA T-score, as shown in the EPIDOS prospective cohort (N=7,598) [8].

Serum P1NP (procollagen type I N-terminal propeptide) reflects osteoblast activity. The International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry (IFCC) jointly designated P1NP as the reference standard bone formation marker [9]. It is less affected by meals and shows smaller diurnal swings than CTX.

Pairing both markers creates a resorption-to-formation ratio that guides therapy selection. A high CTX with suppressed P1NP suggests aggressive antiresorptive therapy (a bisphosphonate or denosumab) may be warranted. A low P1NP with relatively normal CTX can indicate adynamic bone or oversuppression in patients already on bisphosphonates, where an anabolic agent like teriparatide (Forteo) or romosozumab (Evenity) might be preferred. BTMs also serve as early treatment-response markers: CTX drops within 4 to 6 weeks of starting alendronate, months before DEXA shows any density change.

Metabolic Panel and Renal Function

A basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) is standard alongside DEXA for several reasons. Serum creatinine and estimated GFR (eGFR) screen for chronic kidney disease (CKD), which causes renal osteodystrophy through phosphate retention, impaired 1,25-dihydroxyvitamin D synthesis, and secondary hyperparathyroidism. CKD-mineral bone disorder affects virtually all patients with stage 4 or 5 CKD and can appear as early as stage 3 (eGFR <60 mL/min) [10].

Serum phosphorus reveals phosphate-wasting disorders (like X-linked hypophosphatemia) or phosphate retention in CKD. Alkaline phosphatase (ALP), included in a CMP, is an older but still useful bone formation marker. An isolated ALP elevation with normal liver enzymes points toward high bone turnover, Paget disease, or osteomalacia.

Serum magnesium is worth adding. Hypomagnesemia impairs PTH secretion and causes end-organ PTH resistance. Proton pump inhibitor (PPI) use, common in older adults, is a recognized cause of both hypomagnesemia and fracture risk per an FDA drug safety communication [11].

Thyroid Function: TSH

Hyperthyroidism accelerates bone turnover and is a well-established, reversible cause of osteoporosis. Even subclinical hyperthyroidism (suppressed TSH with normal free T4 and free T3) increases fracture risk. A 2015 meta-analysis of 70,298 participants found that subclinical hyperthyroidism was associated with a 36% increased risk of hip fracture (HR 1.36 to 95% CI 1.13 to 1.64) [12].

A TSH level alone is sufficient for screening. If TSH is suppressed (<0.4 mIU/L), follow up with free T4 and free T3. Patients on levothyroxine for hypothyroidism are at particular risk of iatrogenic oversuppression, making TSH an essential part of every osteoporosis workup.

The AACE 2020 guidelines include TSH in their recommended first-tier laboratory evaluation for all patients with newly diagnosed osteoporosis [6].

When to Go Deeper: Second-Tier Tests

Not every patient needs a full secondary workup, but specific clinical scenarios trigger additional labs. The Endocrine Society and AACE recommend second-tier testing when first-line labs are unrevealing, when Z-scores fall below -2.0, or when fractures occur despite treatment [3][6].

Celiac serologies (tissue transglutaminase IgA plus total IgA). Celiac disease is present in up to 3.4% of patients with osteoporosis, compared with about 1% in the general population, based on a meta-analysis of 15 studies (N=3,188 osteoporosis patients) published in the Archives of Osteoporosis [13]. Because celiac disease impairs calcium and vitamin D absorption and is treatable with a gluten-free diet, screening is cost-effective in unexplained bone loss.

24-hour urine calcium. This test distinguishes absorptive hypercalciuria (excess calcium in urine wastes skeletal stores) from low urinary calcium, which suggests malabsorption or vitamin D deficiency. A 24-hour urinary calcium below 50 mg suggests significant malabsorption. Values above 300 mg in men or 250 mg in women indicate hypercalciuria.

Serum protein electrophoresis (SPEP) and free light chains. Multiple myeloma causes lytic bone lesions and generalized osteoporosis. The American Cancer Society notes that bone disease occurs in approximately 80% of myeloma patients at diagnosis [14]. SPEP is appropriate in older adults with unexplained osteoporosis, especially when accompanied by anemia, elevated total protein, or back pain.

Testosterone (total and free) in men. Hypogonadism is the most common secondary cause of osteoporosis in men. The Endocrine Society guideline on testosterone therapy recommends measuring morning total testosterone in all men with osteoporosis or low-trauma fracture [15].

Cortisol testing. Overnight dexamethasone suppression test or 24-hour urine free cortisol screens for Cushing syndrome. Endogenous hypercortisolism causes rapid, severe bone loss, particularly at trabecular sites like the spine.

How Normal DEXA Ranges Guide Test Selection

DEXA results directly influence how aggressively to pursue paired labs. Here is a clinical decision framework.

T-score -1.0 to -1.5 (mild osteopenia). Minimum labs: 25-hydroxyvitamin D, calcium, BMP. This group often needs reassurance and lifestyle counseling rather than pharmacotherapy. A vitamin D level guides supplementation dosing.

T-score -1.5 to -2.5 (moderate osteopenia to threshold osteoporosis). Add: PTH, TSH, CTX or P1NP. The FRAX fracture risk calculator, which incorporates BMD along with clinical risk factors, determines whether pharmacotherapy is indicated. The USPSTF recommends screening women 65 and older and younger postmenopausal women whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman [16].

T-score -2.5 or below, or fragility fracture at any T-score. Full first-tier and second-tier workup: 25-hydroxyvitamin D, PTH, calcium, phosphorus, BMP/CMP with eGFR, ALP, TSH, CBC, CTX, P1NP, 24-hour urine calcium, SPEP, celiac serologies. In men, add morning total testosterone. The 2020 AACE guidelines describe this as the "comprehensive metabolic assessment" tier [6].

Premenopausal women or men under 50 with Z-score below -2.0. This is a red flag. Order everything in the tier above plus cortisol screening and consider referral to endocrinology. As the ISCD notes, the diagnosis in this population is "low bone density for age," not osteoporosis, and a secondary cause is found in the majority of cases [4].

Interpreting Results in Context

Lab values do not exist in isolation. A "normal" vitamin D of 22 ng/mL might look adequate on paper, but in a patient with a T-score of -2.8 and elevated PTH of 85 pg/mL (reference range 15 to 65), that level is functionally insufficient. The Endocrine Society recommends a target of 30 ng/mL or above for patients with osteoporosis [5]. Treat the patient, not the reference range.

Similarly, a normal CTX does not rule out active bone loss. Patients on oral bisphosphonates sometimes show suppressed CTX but continue losing density because of poor medication absorption (bisphosphonates have only 1% to 3% oral bioavailability, per the alendronate FDA label) [17]. Checking a fasting morning CTX 3 to 6 months after starting therapy confirms whether the drug is actually reaching bone.

Repeat DEXA timing matters too. The ISCD recommends follow-up scans at 1 to 2 year intervals for treated patients, and at 2 year intervals for monitoring without treatment, though more frequent scanning can be justified at sites with higher precision (total hip or lumbar spine) [4].

Timing and Specimen Collection

Getting accurate results from paired labs requires attention to pre-analytic variables. CTX must be drawn fasting, before 10:00 AM, because of its diurnal variation (peak in early morning, nadir in afternoon). P1NP has a smaller diurnal window, but fasting morning draws still reduce variability. PTH also fluctuates with a nocturnal peak. Drawing all bone-related labs in a single fasting morning session minimizes variability and patient visits.

25-hydroxyvitamin D is stable and can be drawn at any time. The assay of choice is the total 25(OH)D (measuring both D2 and D3). LC-MS/MS is the gold standard method, though immunoassays are acceptable for clinical purposes [5].

24-hour urine calcium requires the patient to be on their usual diet (not calcium-restricted) for 3 days before and during the collection, and to be vitamin D replete. Collecting urine while the patient is vitamin D deficient produces a falsely low result and masks hypercalciuria that will appear once you replete them.